Bayer : Adjusted guidance in Pharma reduces the pressure for H2
>Weak prel. Q2 figures confirmed – low volumes in CS drag on lop line - This morning. Bayer confirmed its weak prel. figures, which were released on 24.7. when the company warned on FY23 results. Group’s Sales are down yoy by 13.8% to € 11bn. Pharma’s sales decreased by 5% to €4,557m with some tailwind coming from Nubeqa™ (sales of €201m nearly doubled) and Kerendia™ (sales more than tripled to €67m), but still at relatively low levels. As expected, global sales of th...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.